

## **Press release**

**Zug, 21 November 2008**

### **Disclosure of shareholdings – HBM BioVentures holds over 5% of its own shares**

With reference to Articles 9 and 17 of the Ordinance of the Federal Banking Commission on Stock Exchanges and Securities Trading (SESTO-SFBC), HBM BioVentures Ltd (SIX: HBMN), Bundesplatz 1, 6300 Zug, announces that it holds a total of 643'000 of its own registered shares directly and indirectly via its wholly-owned subsidiary, HBM BioVentures (Cayman) Ltd., Centennial Towers, 2454 West Bay Road, Grand Cayman, Cayman Islands. The shares correspond to 5.7% of voting rights, thus exceeding the threshold of 5% of voting rights as at 21 November 2008.

For further information, please contact Dr. Joachim Rudolf, CFO HBM BioVentures Ltd, tel.: +41 41 768 11 08, [joachim.rudolf@hbmbioventures.com](mailto:joachim.rudolf@hbmbioventures.com).

#### **Brief profile of HBM BioVentures Ltd**

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds of its CHF 1 billion capital invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

#### **Disclaimer**

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation. A public share offer in the USA would be conducted by means of a prospectus that would be available from HBM BioVentures Ltd and would contain

**HBM BioVentures Ltd**  
Bundesplatz 1  
CH-6300 Zug / Switzerland  
Tel: +41 41 768 11 08  
Fax: +41 41 768 11 09  
[info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



detailed information about the company and its management, as well as the annual financial statements.

**HBM BioVentures Ltd**  
Bundesplatz 1  
CH-6300 Zug / Switzerland  
Tel:+41 41 768 11 08  
Fax:+41 41 768 11 09  
[info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)